Arbutus Biopharma Corporation

Stage 3 · Topping · week 1⚠ 2→3 today

As of Oct 22, 2026, Arbutus Biopharma is in Stage 3, the topping phase, now in its first week (since Oct 22, 2026). It closed at $4.21, 19.3% below its 52-week high and below its 200-day average, which is falling.

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. More about the company

$4.21

+0.75% today

$645M · Small cap

Market Neutral — Fading

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is ABUS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S2 42w

S2 21w

S2 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 6w → S2 42w → S3 8w → S4 10w → S1 2w → S4 8w → S1 5w → S4 4w → S1 2w → S2 21w → S3 11w → S2 5w → S3 2w → S4 5w → S1 1w → S2 15w → S3 1w current

Total tracked: 165 weeks across 18 stage runs.

ABUS among Biotechnology208th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…208	ABUSArbutus Biopharma Corporation	Stage 3 · wk 1	49	−13.2%

vs 52W High

-19.3%

$3.67 lo$5.22 hi

19.3% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-6.6%

200 DMA: $4.51 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.42x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.2%

-3.9%

-0.9%

YTD

-11.7%

-6.0%

Scan Membership

Breakout Watch

Latest: 2024-01-30

6 appearances in last 60 days. First seen: 2020-01-09.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S32→3

Wk 1 · Vol 0.42x

2026-10-21S2

Wk 15 · Vol 0.47x

2026-10-20S2

Wk 15 · Vol 0.36x

2026-10-19S2

Wk 15 · Vol 0.34x

2026-10-16S2

Wk 15 · Vol 0.80x

2026-10-15S2

Wk 15 · Vol 0.40x

2026-10-14S2

Wk 14 · Vol 0.43x

2026-10-13S2

Wk 14 · Vol 0.62x

2026-10-12S2

Wk 14 · Vol 0.42x

2026-10-09S2

Wk 14 · Vol 0.57x

2026-10-08S2

Wk 14 · Vol 0.88x

2026-10-07S2

Wk 13 · Vol 0.88x

Moving averages & range

50 DMA

$4.77

200 DMA

$4.51

52W High

$5.22

52W Low

$3.67

5D Low

$4.18

Resistance levels (recent highs)

20d High

$4.86

60d High

$5.21

120d High

$5.22

250d High

$5.22

Next resistance

+15.4%

to 20d High

P/E (TTM)

5.3

Forward -25.5

ROE

+89.6%

Profit margin +84.2%

Dividend Yield

0.00%

P/B 3.2

Arbutus Biopharma: quick answers

What stage is Arbutus Biopharma in?

As of Oct 22, 2026, Arbutus Biopharma (ABUS) is in Stage 3, the topping phase. It entered Stage 3 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Arbutus Biopharma in an uptrend?

Its uptrend has stalled. Arbutus Biopharma is in Stage 3, the topping phase that follows an advance. It trades 6.6% below its 200-day average, which is falling.

How far is Arbutus Biopharma from its 52-week high?

Arbutus Biopharma closed at $4.21 on Oct 22, 2026, 19.3% below its 52-week high of $5.22. Its 52-week low is $3.67.

How has Arbutus Biopharma performed over the past year?

As of Oct 22, 2026, Arbutus Biopharma is down 6.0% over the past year and down 11.7% so far in 2026.

Which sector and industry is Arbutus Biopharma in?

Arbutus Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.